EUVIMEDEUVIMED entdecken
Crossref

CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance

Hye Won Lee iD, Terry Cheuk-Fung Yip iD, Vincent Wai-Sun Wong iD, Young-Suk Lim iD, Henry Lik-Yuen Chan iD, Sang Hoon Ahn iD, Grace Lai-Hung Wong iD, Jonggi Choi iD

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.17933 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Hye Won Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hepatitis B, Chronic, Liver Neoplasms, Hepatitis B Surface Antigens. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: National Evidence-based Healthcare Collaborating Agency, National R & D Program for Cancer Control, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Risk of hepatocellular carcinoma (HCC) persists after hepatitis B surface antigen (HBsAg) seroclearance in patients with chronic hepatitis B (CHB).

Aims

To identify risk factors and construct a predictive model for HCC development.

Methods

We retrospectively analysed patients with CHB with HBsAg seroclearance. Primary outcome was HCC development. Factors identified from a multivariate Cox model in the training cohort, consisting of 3476 patients from two Korean hospitals, were used to construct the prediction model. External validation was performed using data from 5255 patients in Hong Kong.

Results

In the training cohort, HCC occurred in 102 patients during 24,019 person‐years of observation (0.43%/year). Risk scores were assigned to cirrhosis (C:3), age ≥50 years (A:2), male sex (M:3) and platelet count

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularHepatitis B, ChronicLiver NeoplasmsHepatitis B Surface AntigensHumansMaleFemaleMiddle AgedRetrospective StudiesRisk FactorsAdultAgedLiver CirrhosisHong KongRepublic of KoreaRisk AssessmentPlatelet CountAge Factors

Substanzen

Hepatitis B Surface Antigens

Autor:innen und Institutionen

  • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
  • Medical Data Analytics Centre (MDAC), The Chinese University of Hong Kong, Hong Kong, China.
  • Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.
  • Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Internal Medicine, Union Hospital, Hong Kong, China.

ORCID-Profile: Hye Won Lee, Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong, Young-Suk Lim, Henry Lik-Yuen Chan, Sang Hoon Ahn, Grace Lai-Hung Wong, Jonggi Choi

Förderung

  • National Evidence-based Healthcare Collaborating Agency
  • National R & D Program for Cancer Control
  • National Research Foundation of Korea
  • Ministry of Health and Welfare

Zitieren

APA

Lee, H. W., Yip, T. C., Wong, V. W., Lim, Y. S., Chan, H. L., Ahn, S. H., Wong, G. L., & Choi, J. (2024). CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17933

Vancouver

Lee HW, Yip TC, Wong VW, Lim YS, Chan HL, Ahn SH, et al. CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17933

BibTeX
@article{Lee2024,
  author = {Lee, Hye Won and Yip, Terry Cheuk-Fung and Wong, Vincent Wai-Sun and Lim, Young-Suk and Chan, Henry Lik-Yuen and Ahn, Sang Hoon and Wong, Grace Lai-Hung and Choi, Jonggi},
  title = {CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.17933}
}
Kostenlos starten →